GPT-Rosalind
2026-04-17 · Publisher : OpenAI · Domain : Artificial Intelligence
OpenAI présente GPT-Rosalind, un modèle de raisonnement spécialisé en biologie, découverte de médicaments et médecine translationnelle, proposé en aperçu de recherche par accès de confiance.
What changes
- Optimized for chemistry, protein engineering and genomics, with better use of scientific tools and databases.
- Free Codex “Life Sciences” plugin, connecting the models to more than 50 tools and public data sources.
- Partners named: Amgen, Moderna, Allen Institute, Thermo Fisher Scientific.
- Access initially reserved for qualified Enterprise customers in the United States, through a trusted access program.
- Out of preview and opened worldwide to eligible organizations on September 11, 2026.
OpenAI introduces GPT-Rosalind, a reasoning model specialized in biology, drug discovery and translational medicine, offered as a research preview through trusted access. ### Specifications - Availability: ChatGPT, Codex and API for approved organizations. - API identifier: gpt-rosalind-research. - Context and knowledge cutoff: not disclosed in the pages read. - Name is a tribute to Rosalind Franklin. ### Pricing | Input | Cached input | Output | | --- | --- | --- | | $5.00 | $0.50 | $25.00 | Price per million tokens (USD), billing starting October 5, 2026. Pricing not disclosed at the April announcement. ### Benchmarks On BixBench, OpenAI claims leading performance among models with published scores, with no value given in the text. On LABBench2, the model beats GPT-5.4 on 6 tasks out of 11. With Dyno Therapeutics, the best submissions out of ten attempts exceed the 95th percentile of human experts in RNA sequence-function prediction. Scores published by the vendor. ### Key takeaways The first vertical model offering from OpenAI for pharmaceutical research, under strict access control. Enterprise deployment goes through prior qualification, not through the standard API.
Links
Tags : LLM, OpenAI, Sciences de la vie, Biologie, Accès restreint